Intrust Bank NA decreased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,612 shares of the biopharmaceutical company’s stock after selling 52 shares during the period. Intrust Bank NA’s holdings in Bristol-Myers Squibb were worth $1,066,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Lebenthal Asset Management LLC raised its position in Bristol-Myers Squibb by 0.6% in the fourth quarter. Lebenthal Asset Management LLC now owns 169,244 shares of the biopharmaceutical company’s stock worth $9,891,000 after buying an additional 1,085 shares during the period. RB Capital Management LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $364,000. Empire Life Investments Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $2,960,000. ARS Investment Partners LLC raised its stake in Bristol-Myers Squibb by 6.9% in the fourth quarter. ARS Investment Partners LLC now owns 179,008 shares of the biopharmaceutical company’s stock worth $10,461,000 after buying an additional 11,541 shares during the last quarter. Finally, Clough Capital Partners L P raised its stake in Bristol-Myers Squibb by 95.8% in the fourth quarter. Clough Capital Partners L P now owns 399,209 shares of the biopharmaceutical company’s stock worth $23,330,000 after buying an additional 195,292 shares during the last quarter. 69.68% of the stock is owned by institutional investors.
Shares of Bristol-Myers Squibb Company (BMY) traded down 0.62% during trading on Friday, hitting $56.42. The stock had a trading volume of 4,809,885 shares. The firm has a market cap of $92.52 billion, a P/E ratio of 20.61 and a beta of 1.17. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $60.45. The firm has a 50 day moving average price of $55.95 and a 200 day moving average price of $54.96. Bristol-Myers Squibb also was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 781 put options on the company. This is an increase of 117% compared to the typical daily volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company posted $0.69 EPS. On average, equities analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.
COPYRIGHT VIOLATION NOTICE: “Intrust Bank NA Lowers Position in Bristol-Myers Squibb Company (NYSE:BMY)” was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/bristol-myers-squibb-company-nysebmy-shares-sold-by-intrust-bank-na-updated-updated.html.
A number of analysts have commented on the company. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday. Cowen and Company set a $65.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, August 14th. Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price for the company. in a report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Finally, BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $62.12.
In related news, Director Theodore R. Samuels II purchased 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.